RTIOXA-43

• CAT Number: I041063
• CAS Number: 2832067-72-6
• Molecular Formula: C37H37N5O5S
• Molecular Weight: 663.79
• Purity: ≥95%
• Synonyms: N-[2-[3-[[2-methoxy-5-[3-[methyl(pyridin-4-ylmethyl)carbamoyl]phenyl]phenyl]sulfonylamino]anilino]ethyl]-3-methylbenzamide
• InChI: InChI=1S/C37H37N5O5S/c1-26-7-4-9-30(21-26)36(43)40-20-19-39-32-11-6-12-33(24-32)41-48(45,46)35-23-29(13-14-34(35)47-3)28-8-5-10-31(22-28)37(44)42(2)25-27-15-17-38-18-16-27/h4-18,21-24,39,41H,19-20,25H2,1-3H3,(H,40,43)
• InChIKey: WIANBLHLJZGLLG-UHFFFAOYSA-N
• SMILES: CC1=CC(=CC=C1)C(=O)NCCNC2=CC(=CC=C2)NS(=O)(=O)C3=C(C=CC(=C3)C4=CC(=CC=C4)C(=O)N(C)CC5=CC=NC=C5)OC

RTIOXA-43（Cat No.:I041063）is a synthetic compound under investigation for its potential therapeutic applications in various disease areas, including cancer and inflammation. It belongs to a class of molecules that are designed to target specific molecular pathways involved in disease progression. RTIOXA-43 has shown promise in preclinical studies for its ability to modulate key enzymes and signaling pathways that influence cell growth and survival. While its exact mechanism of action is still being explored, RTIOXA-43 is being studied for its potential as a targeted treatment option in oncology and inflammatory disorders.